This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
In Q2 2026, global pharma investment totaled $9.1 billion, up 16.7% from Q1 2026. Deal volume also edged up 0.6% to 178 transactions. Oncology emerged as the top therapy area with 79 deals backed by 265 investors.
In Q2 2026, global pharma investment totaled $9.1 billion, up 16.7% from Q1 2026. Deal volume also edged up 0.6% to 178 transactions. Oncology emerged as the top therapy area with 79 deals backed by 265 investors.
Scope
- This report provides an overview of VC investment activity globally in Q2 2026 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q2 2026 in the Pharma sector.
Reasons to Buy
- Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Isomorphic Labs
- Newlimit
- Ollin Biosciences
- CellCentric
- Osanni Bio
- Bionyra Pharma
- Windward Bio
- Sidewinder Therapeutics
- Beren Therapeutics
- Beeline Medicines
- Stipple Bio
- Contraline
- Terremoto Biosciences
- Biossil
